Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
Date:10/22/2008

antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candida
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Avicena Group to Present at Noble Financial Conference
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Spherix Incorporated ... and monetization of intellectual property, today announced that the ... patents to the Company in the month of August ... patents.  The issued patents are: ... , U.S.RE45,081 issued August 19, 2014; and , ...
(Date:9/1/2014)... Reportlinker.com announces that a new market ... India Solid Waste Management Vehicles Market Forecast ... In India ... responsible for complete handling and regulation of solid ... 135,000 MT solid waste is generated daily in ...
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
Breaking Biology Technology:Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
... Innovation, Inc. (BHI), a regional private-public partnership focusing ... early-stage funding in Central Maryland, announced today the appointment ... at Qiagen , to its Board of ... to our board," said Scott Carmer, BioHealth Innovation, Inc. ...
... by Kathleen Eggleson, a research scientist in the Center ... of Notre Dame, provides an example of a nanotechnology-related ... The world of nanotechnology, which involves science and ... But like most new advances, the application of that ...
... On April 19, 2012, GeneLink,s common stock began trading ... this will be temporary as it is due to the ... for the period ended December 31, 2011.  The Company anticipates ... on Form 10K for the period ended December 31, 2011 ...
Cached Biology Technology:BioHealth Innovation, Inc. Appoints Qiagen's Douglas Liu to Board of Directors 2Notre Dame paper examines nanotechnology-related safety and ethics problem 2Notre Dame paper examines nanotechnology-related safety and ethics problem 3GeneLink Anticipates Completion of Audit 2
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... the same DNA sequence their genetic information. How ... in the different parts of the body are so ... master plan, an additional regulatory layer exists that determines ... This mechanism involves modifications of genome-bound histone proteins or ... It acts on top of the genetic information and ...
(Date:9/2/2014)... the September issue of The FASEB Journal ... to diagnose the leading cause of blindness in ... occurred. This advance involves quantifying the early molecular ... retinal vessels. Using new probes developed by scientists, ... development of diabetic retinopathy. , "My goal is ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... Scientists have discovered that a stem cell factor overexpressed ... brain injury promotes tumor survival by inducing angiogenesis. The ... Cell, examines the interaction between tumor cells and surrounding ... more effective therapeutics for one of the most lethal ...
... In an unexpected discovery, scientists at Jefferson Medical College ... virus protein can turn a "safe" virus extremely deadly. ... vaccine they previously created against rabies in wildlife, making ... a molecular mechanism involved in making the rabies virus ...
... disease in the brain of the fruit fly, researchers ... proteins previously associated with cancer. , The findings are ... Brigham and Women's Hospital, Harvard Medical School, and the ... not divide. It is therefore perplexing that in Alzheimer's ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Jefferson researchers building a better rabies vaccine 2
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: